Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated:  12/31/1969
University of Arizona
834
mi
from
Tucson, AZ
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated: 12/31/1969
University of Arizona
834
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated:  12/31/1969
Childrens Health Care
605
mi
from
Wheeling, IL
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated: 12/31/1969
Childrens Health Care
605
mi
from
Wheeling, IL
Click here to add this to my saved trials
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
153
mi
from
Oklahoma City, OK
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
153
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated:  12/31/1969
Sutter Institute for Medical Research
1282
mi
from
Roseville, CA
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated: 12/31/1969
Sutter Institute for Medical Research
1282
mi
from
Roseville, CA
Click here to add this to my saved trials
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated:  12/31/1969
State University of New York (SUNY)
1194
mi
from
Syracuse, NY
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated: 12/31/1969
State University of New York (SUNY)
1194
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health
976
mi
from
Winston-Salem, NC
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health
976
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated:  12/31/1969
UH Rainbow Babies and Children's Hospital
899
mi
from
Cleveland, OH
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
A Study to Monitor the Use of an Amino Acid-Based Infant Formula
Status: Enrolling
Updated: 12/31/1969
UH Rainbow Babies and Children's Hospital
899
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  12/31/1969
BRB Site
mi
from
Chula Vista, CA
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 12/31/1969
BRB Site
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  12/31/1969
BRB Site
mi
from
Miami, FL
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 12/31/1969
BRB Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  12/31/1969
BRB Site
mi
from
Orlando, FL
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 12/31/1969
BRB Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  12/31/1969
BRB Site
mi
from
San Antonio, TX
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 12/31/1969
BRB Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  12/31/1969
BRB Site
mi
from
Nedlands,
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 12/31/1969
BRB Site
mi
from
Nedlands,
Click here to add this to my saved trials
The Role of Microparticles as a Biomarker
The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
1121
mi
from
Rochester, NY
The Role of Microparticles as a Biomarker
The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
1121
mi
from
Rochester, NY
Click here to add this to my saved trials
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated:  12/31/1969
National Research Institute
1170
mi
from
Los Angeles, CA
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated: 12/31/1969
National Research Institute
1170
mi
from
Los Angeles, CA
Click here to add this to my saved trials
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
1123
mi
from
DeLand, FL
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
1123
mi
from
DeLand, FL
Click here to add this to my saved trials
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research, LLC
1123
mi
from
Orange City, FL
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research, LLC
1123
mi
from
Orange City, FL
Click here to add this to my saved trials
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated:  12/31/1969
Qps-Mra, Llc
1320
mi
from
South Miami, FL
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated: 12/31/1969
Qps-Mra, Llc
1320
mi
from
South Miami, FL
Click here to add this to my saved trials
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated:  12/31/1969
Sterling Research Group
725
mi
from
Cincinnati, OH
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated: 12/31/1969
Sterling Research Group
725
mi
from
Cincinnati, OH
Click here to add this to my saved trials
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated:  12/31/1969
WR-ClinSearch, LLC
726
mi
from
Chattanooga, TN
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated: 12/31/1969
WR-ClinSearch, LLC
726
mi
from
Chattanooga, TN
Click here to add this to my saved trials
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of Texas, Inc.
570
mi
from
San Antonio, TX
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of Texas, Inc.
570
mi
from
San Antonio, TX
Click here to add this to my saved trials
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated:  12/31/1969
National Clinical Research, Inc.
1106
mi
from
Richmond, VA
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated: 12/31/1969
National Clinical Research, Inc.
1106
mi
from
Richmond, VA
Click here to add this to my saved trials
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated:  12/31/1969
Stand-Up MRI of Miami
1321
mi
from
Miami, FL
6-week Safety and PD Study in Adults With NAFLD
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status: Enrolling
Updated: 12/31/1969
Stand-Up MRI of Miami
1321
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
Rosalind Franklin University
614
mi
from
North Chicago, IL
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
Rosalind Franklin University
614
mi
from
North Chicago, IL
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
Univ of North Carolina
1043
mi
from
Chapel Hill, NC
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
Univ of North Carolina
1043
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
Banner University Medical Center
851
mi
from
Phoenix, AZ
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
Banner University Medical Center
851
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
UCLA Olive View
1174
mi
from
Sylmar, CA
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
UCLA Olive View
1174
mi
from
Sylmar, CA
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
University of Miami
1319
mi
from
Miami, FL
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
University of Miami
1319
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
Village Podiatry Centers
857
mi
from
Smyrna, GA
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
Village Podiatry Centers
857
mi
from
Smyrna, GA
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
Ochsner Medical Center
694
mi
from
New Orleans, LA
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
Ochsner Medical Center
694
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
St Luke's - Roosevelt Hospital Center
1288
mi
from
New York, NY
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
St Luke's - Roosevelt Hospital Center
1288
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
618
mi
from
Nashville, TN
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
Futuro Clinical Trials, LLC
798
mi
from
McAllen, TX
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
Futuro Clinical Trials, LLC
798
mi
from
McAllen, TX
Click here to add this to my saved trials
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated:  12/31/1969
Carilion Clinic
979
mi
from
Roanoke, VA
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Status: Enrolling
Updated: 12/31/1969
Carilion Clinic
979
mi
from
Roanoke, VA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
CARE CLINIC - UCLA Medical Center
1179
mi
from
Los Angeles, CA
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
CARE CLINIC - UCLA Medical Center
1179
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
1401 N. Palm Canyon
1081
mi
from
Palm Springs, CA
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
1401 N. Palm Canyon
1081
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
Trials Unit Div of Infectious and Immunologic Diseases
1283
mi
from
Sacramento, CA
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
Trials Unit Div of Infectious and Immunologic Diseases
1283
mi
from
Sacramento, CA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
UCSD Antiviral Research Center
1142
mi
from
San Diego, CA
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
UCSD Antiviral Research Center
1142
mi
from
San Diego, CA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco - Div. of Endocrinology
1341
mi
from
San Francisco, CA
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco - Div. of Endocrinology
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente
1340
mi
from
San Francisco, CA
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente
1340
mi
from
San Francisco, CA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
Northern California Institute for Research and Education
1343
mi
from
San Francisco, CA
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
Northern California Institute for Research and Education
1343
mi
from
San Francisco, CA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA Medical Ctr Research & Education Institute
1176
mi
from
Torrance, CA
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA Medical Ctr Research & Education Institute
1176
mi
from
Torrance, CA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
AIDS Alliance
1174
mi
from
West Hollywood, CA
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
AIDS Alliance
1174
mi
from
West Hollywood, CA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
University of Colorado Health Sciences Center
407
mi
from
Denver, CO
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
University of Colorado Health Sciences Center
407
mi
from
Denver, CO
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
Office Of Dr Gary Richmond
1308
mi
from
Fort Lauderdale, FL
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
Office Of Dr Gary Richmond
1308
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
3661 South Miami Avenue
1322
mi
from
Miami, FL
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
3661 South Miami Avenue
1322
mi
from
Miami, FL
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
Care Resources
1319
mi
from
Miami, FL
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
Care Resources
1319
mi
from
Miami, FL
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
Infectious Disease Associates
1142
mi
from
Sarasota, FL
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
Infectious Disease Associates
1142
mi
from
Sarasota, FL
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
AIDS Research Consortium of Atlanta
801
mi
from
Atlanta, GA
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
AIDS Research Consortium of Atlanta
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
608
mi
from
Chicago, IL
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
608
mi
from
Chicago, IL
Click here to add this to my saved trials